Experiences with vaccines against cutaneous leishmaniasis: of men and mice.
The need for a vaccine(s) against cutaneous leishmaniasis and the populations at risk for whom such vaccines should be developed are briefly discussed. The current human vaccine studies are reviewed, as are some experimental mouse studies with emphasis on Leishmania major infection relevant to vaccine development. Based on the information available from the mouse model and those data which are being sought in human studies, the benign nature of the cutaneous disease, the ease with which L. major can be manipulated to yield the required material, and the ongoing practice of leishmanization which allows rapid evaluation of candidate vaccine(s), it is suggested that a vaccine, at least against L. major, is imminent in the not too distant future.
Modabber
F
F
UNDP/World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland.
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D007895:Leishmania tropica / Q000276:immunology*; D007896:Leishmaniasis / Q000517:prevention & control*; D051379:Mice; D014611:Vaccination; D014612:Vaccines
D014612:Vaccines